WO2022227987A1 - Heterocyclic derivative and preparation method therefor and use thereof - Google Patents

Abstract

The present invention relates to a heterocyclic derivative and a preparation method therefor and an application thereof in medicine. Specifically, the present invention relates to a heterocyclic derivative represented by general formula (I) and a preparation method therefor and a pharmaceutically acceptable salt thereof, and a use thereof as therapeutic agents, especially as KRas G12D inhibitors, wherein the definition of substituents in the general formula (I) is the same as the definition in the description.

Description

Heterocyclic derivatives and preparation methods and uses thereof technical field

The present invention relates to a heterocyclic derivative, a preparation method thereof, a pharmaceutical composition containing the derivative and its use as a therapeutic agent, especially as a K-Ras GTPase inhibitor.

Background technique

RAS represents a group of closely related monomeric globular proteins (21 kDa molecular weight) that have 189 amino acids and are associated with the plasma membrane and bind GDP or GTP. Under normal developmental or physiological conditions, RAS is activated upon receipt of growth factors and various other extracellular signals, and is responsible for regulating functions such as cell growth, survival, migration, and differentiation. RAS acts as a molecular switch, and the on/off state of RAS proteins is determined by nucleotide binding, with the active signaling conformation bound to GTP and the inactive conformation bound to GDP. When RAS contains bound GDP, it is in a dormant or quiescent or off state and is "inactive". When cells respond to exposure to certain growth-promoting stimuli, RAS is induced to convert bound GDP to GTP. With GTP bound, RAS is "on" and is able to interact with and activate other proteins (its "downstream targets"). The RAS protein itself has a very low intrinsic ability to hydrolyze GTP back to GDP and thereby turn itself into the off state. Switching RAS off requires exogenous proteins called GTPases activating proteins (GAPs), which interact with RAS and greatly facilitate the conversion of GTP to GDP. Any mutation in RAS that affects its ability to interact with GAP or convert GTP back to GDP will result in prolonged activation of the protein and thus an extended signal to the cell that tells it to continue growing and split. So these signals allow cells to grow and divide, and overactive RAS signaling may ultimately lead to cancer.

Structurally, RAS proteins contain a G domain responsible for the enzymatic activity of RAS, guanine nucleotide binding and hydrolysis (GTPase reaction). It also includes a C-terminal extension called the CAAX box, which can be post-translationally modified and target the protein to the membrane. The G domain is approximately 21-25 kDa in size and contains a phosphate-binding loop (P-loop). The P-loop represents the pocket in the protein that binds nucleotides, and this is the rigid part of the domain with conserved amino acid residues necessary for nucleotide binding and hydrolysis (glycine 12, threo amino acid 26 and lysine 16). The G domain also contains the so-called switch I region (residues 30-40) and switch II region (residues 60-76), both of which are the dynamic part of the protein as it switches between rest and load states capability is often denoted as a "spring loaded" mechanism. The main interaction is the hydrogen bond formed by threonine-35 and glycine-60 with the γ-phosphate of GTP, which allows switch I and switch II regions, respectively, to maintain their active conformations. After hydrolysis of GTP and release of phosphate, both relax to the inactive GDP conformation.

Among RAS family members, oncogenic mutations were most frequently found in KRAS (85%), whereas NRAS (12%) and HRAS (3%) were less common. KRAS mutations are prevalent in the three most lethal cancer types in the United States: pancreatic cancer (95%), colorectal cancer (45%), and lung cancer (25%). KRAS mutations are also found in other cancer types including carcinoma, diffuse large B-cell lymphoma, rhabdomyosarcoma, cutaneous squamous cell carcinoma, cervical cancer, testicular germ cell carcinoma, etc. Rarely found (<2%). In non-small cell lung cancer (NSCLC), KRAS G12C is the most common mutation, accounting for nearly half of all KRAS mutations, followed by G12V and G12D. In non-small cell lung cancer, the increased frequency of allele-specific mutations is mostly due to classic smoking-induced mutations (G:C to T:A substitutions), resulting in KRAS G12C (GGT to TGT) and G12V (GGT) to GTT) mutation.

Large genomic studies have shown that KRAS mutations in lung cancer, including G12C, are mutually exclusive with other known driver oncogenic mutations in NSCLC, including EGFR, ALK, ROS1, RET, and BRAF, indicating the uniqueness of KRAS mutations in lung cancer. Meanwhile, KRAS mutations frequently co-occur with certain co-mutations, such as STK11, KEAP1, and TP53, which cooperate with mutated RAS to transform cells into highly malignant and aggressive tumor cells.

Three RAS oncogenes constitute the most frequently mutated gene family in human cancers. Disappointingly, despite more than three decades of research efforts, there is still no clinically effective anti-RAS therapy, and targeting this gene with small molecules is challenging. Therefore, there is an urgent need in the art for small molecules for targeting RAS (eg, K-RAS, H-RAS and/or N-RAS) and using them to treat various diseases, such as cancer.

At present, there is fierce competition for clinical development of KRas G12D inhibitors at home and abroad. Among them, MRTX-1133, a KRas G12D inhibitor developed by Mirati Therapeutics Inc, has entered the preclinical stage for the treatment of colorectal tumors, non-small cell lung cancer and pancreatic cancer. . At present, there are a few patent applications for KRas G12D inhibitors published, including WO2021041671 of Mirati Therapeutics Inc. Although some progress has been made in the research and application of KRas G12D inhibitors, the room for improvement is still huge, and it is still necessary to continue the research and development of new KRas G12D inhibitors.

SUMMARY OF THE INVENTION

The object of the present invention is to provide a heterocyclic derivative represented by the general formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof:

in:

Ring B is selected from aryl, heteroaryl or fused rings;

Q is selected from N or CR ^a ;

Y is selected from a bond, -O- or ^-NRb ;

R ^a is selected from hydrogen atom, halogen, alkyl, alkoxy or cyano; wherein said alkyl or alkoxy is optionally further selected from one or more halogens, hydroxy, cyano, alkyl or alkane substituted by an oxy substituent;

R ^b is selected from a hydrogen atom or an alkyl group;

R ^c is selected from hydrogen atom, halogen, cyano, alkyl or alkoxy; wherein said alkyl or alkoxy is optionally further selected by one or more of halogen, hydroxy, cyano, alkyl or alkoxy substituted by the substituent of oxy; R ^c is preferably halogen, more preferably fluorine or chlorine;

R ¹ is selected from -L-cycloalkyl, -L-(6-membered to 9-membered) monocyclic heterocyclic group, -L-bicyclic heterocyclic group, -L-tricyclic heterocyclic group, -L-aryl, -L-heteroaryl or -L- fused ring; wherein said cycloalkyl, (6-9 membered) monocyclic heterocyclic group, bicyclic heterocyclic group, -tricyclic heterocyclic group, aryl, The heteroaryl or fused ring is optionally further selected from one or more groups selected from the group consisting of alkyl, halogen, haloalkyl, hydroxyalkyl, benzyl, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl base, =O, -OR ⁵ , -C(O)R ⁵ , -C(O)OR ⁵ , -NHC(O)R ⁵ , -NHC(O)OR ⁵ , -NR ⁶ R ⁷ , -C( O) NR ⁶ R ⁷ , -CH ₂ NHC(O)OR ⁵ , -CH ₂ NR ⁶ R ⁷ or -S(O) _r R ⁵ substituent;

L is each independently selected from a bond or a -C ₁ -C ₆ alkylene group, wherein said alkylene group is optionally further substituted with one or more R ^D ;

R ^D is each independently selected from a hydrogen atom, halogen, hydroxy or hydroxymethyl;

Alternatively, two R ^D attached to the same carbon atom, together with the attached carbon atom, form a cycloalkyl; preferably cyclopropyl;

R ² are the same or different, each independently selected from hydrogen atom, halogen, hydroxyl, alkyl or alkoxy, preferably hydrogen atom or alkyl;

The two ^R3 together with the atoms to which they are attached form a cycloalkyl or heterocyclyl;

The condition is that when Q is chosen from N,

not selected

R ⁴ are the same or different, each independently selected from a hydrogen atom, an alkyl group, a halogen, a nitro group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, =O, - OR ⁵ , -C(O)R ⁵ , -C(O)OR ⁵ , -NHC(O)R ⁵ , -NHC(O)OR ⁵ , -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -CH ₂ NHC(O)OR ⁵ , -CH ₂ NR ⁶ R ⁷ or -S(O) _r R ⁵ ; wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl The radical or heteroaryl is optionally further selected from one or more of alkyl, halogen, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, ^-OR5 , -C (O)R ⁵ , -C(O)OR ⁵ , -NHC(O)R ⁵ , -NHC(O)OR ⁵ , -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -CH ₂ NHC (O) OR ⁵ , -CH ₂ NR ⁶ R ⁷ or -S(O) _r R ⁵ substituent;

R ⁵ is each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclyl group, aryl group or heteroaryl group is any selected further by one or more selected from the group consisting of hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O , -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , -SO ₂ NR ⁹ R ¹⁰ or - Substituted by the substituent of NR ⁹ C(O)R ¹⁰ ;

R ⁶ and R ⁷ are each independently selected from a hydrogen atom, a hydroxyl group, a halogen, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, alkoxy group, A cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally further selected from one or more groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl radical, heteroaryl, =O, -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , - SO ₂ NR ⁹ R ¹⁰ or the substituent of -NR ⁹ C(O)R ¹⁰ ;

Alternatively, R ⁶ and R ⁷ together with the atoms to which they are attached form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) _r , and the The 4-8 membered heterocyclic group is optionally further selected from one or more groups selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl , =O, -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , -SO ₂ NR ⁹ R ¹⁰ or -NR ⁹ C(O)R ¹⁰ is substituted by the substituent;

R ⁸ , R ⁹ and R ¹⁰ are each independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclic group , aryl or heteroaryl are optionally further selected from one or more groups selected from hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl , substituted by a substituent of a carboxyl group or a carboxylate group;

m is selected from 0, 1, 2, 3 or 4;

n is selected from 0, 1, 2 or 3;

r is 0, 1 or 2.

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I), or stereoisomers, tautomers or pharmaceutically acceptable salts thereof, are represented by the general formula (II) The compounds shown or their stereoisomers, tautomers or their pharmaceutically acceptable salts:

wherein: ring B, R ¹ , R ² , R ⁴ , R ^c , Y, m and n are as defined in general formula (I).

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I) or (II), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein:

R ¹ is -L-bicyclic heterocyclic group; wherein said bicyclic heterocyclic group is optionally further substituted by one or more substituents selected from alkyl, halogen, alkoxy or =O; wherein said Halogen is preferably fluorine;

L is selected from a bond or a -C ₁ -C ₃ alkylene group, wherein said alkylene group is optionally further substituted by one or more R ^D ;

R ^D is each independently selected from a hydrogen atom, halogen, hydroxy or hydroxymethyl;

Alternatively, two R ^D , attached to the same carbon atom, together with the attached carbon atom form a cycloalkyl; preferably cyclopropyl.

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I) or (II), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein:

L is selected from bond, -CH ₂ -, -CH ₂ CH ₂ - or

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I) or (II), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein R1 is selected from ^:

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein two R ³ are connected to them The atoms together form a 4-8 membered cycloalkyl or 4-8 membered heterocyclyl.

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I) or (II), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein:

R ⁴ are the same or different, each independently selected from a hydrogen atom, an alkyl group, a halogen, an alkoxy group, an alkynyl group, a hydroxyl group, an amino group, a hydroxyalkyl group, a haloalkyl group or a haloalkoxy group;

Preferred is a hydrogen atom, methyl, fluorine, chlorine, hydroxy, amino, hydroxymethyl or ethynyl.

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I) or (II), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein:

Ring B is selected from phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, indolyl, indazolyl, benzothiazolyl, tetralinyl,

Preferred are naphthyl and benzothiazolyl.

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I) or (II), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein

selected from the following groups:

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I), their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein

selected from the following groups:

In a preferred embodiment of the present invention, the heterocyclic derivatives represented by the general formula (I) or (II), or their stereoisomers, tautomers or their pharmaceutically acceptable salts, wherein R ^c is selected from from halogen, preferably fluorine.

Typical compounds of the present invention include, but are not limited to:

or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof.

NOTE: If there is a discrepancy between the drawn structure and the given name of that structure, the drawn structure will be given greater weight. In another aspect, the present invention provides a pharmaceutical composition comprising an effective dose of the compound of general formula (I) or (II) or its stereoisomer, tautomer or A pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient or a combination thereof.

In another aspect, the present invention provides a method for inhibiting KRas G12D enzyme, wherein the method comprises administering to a patient a pharmaceutical composition containing an effective dose of general formula (I) or (II) The compound or its stereoisomers, tautomers or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, excipients or combinations thereof.

The present invention also provides a compound of the general formula (I) or (II) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, which is prepared for the treatment by KRas Use in the medicine of the disease mediated by G12D mutation, wherein the disease mediated by KRas G12D mutation is selected from cancer, wherein the cancer is selected from cardiac myxoma, lung cancer, gastric cancer, colorectal cancer, rectal cancer, Pancreatic cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, cholangiocarcinoma, chondrosarcoma, multiple myeloma, uterine cancer, cervical cancer, seminoma, malignant melanoma, skin squamous cell carcinoma, adrenal neuroblastoma , myeloid leukemia, acute lymphoblastic leukemia or glioblastoma, preferably pancreatic cancer, colorectal cancer, rectal cancer and lung cancer; wherein said lung cancer is selected from non-small cell lung cancer or small cell lung cancer.

In another aspect, the present invention provides a compound of the general formula (I) or (II) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation Use in KRas G12D inhibitors.

Another aspect of the present invention relates to a method of preventing and/or treating a disease mediated by KRas G12D mutation, comprising administering to a patient a therapeutically effective dose of a compound of general formula (I) or (II) or its interconversion Isomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same.

The present invention also provides a compound of the general formula (I) or (II) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a compound for the treatment of cancer. Use in medicine, wherein the cancer is selected from cardiac myxoma, lung cancer, gastric cancer, colorectal cancer, rectal cancer, pancreatic cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, cholangiocarcinoma, chondrosarcoma, multiple myeloma , uterine cancer, cervical cancer, seminoma, malignant melanoma, cutaneous squamous cell carcinoma, adrenal neuroblastoma, myeloid leukemia, acute lymphoblastic leukemia or glioblastoma, preferably pancreatic cancer, colorectal cancer cancer, rectal cancer and lung cancer; wherein said lung cancer is preferably non-small cell lung cancer.

The pharmaceutical formulations of the present invention can be topical, oral, transdermal, rectal, vaginal, parenteral, intranasal, intrapulmonary, intraocular, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intradermal , intraperitoneal, subcutaneous, substratum corneum, or by inhalation. Pharmaceutical compositions containing the active ingredient may be in a form suitable for oral administration, such as tablets, dragees, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or Elixirs. Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients suitable for the manufacture of tablets.

The formulations of the present invention are suitably presented in unit dosage form, and such formulations may be prepared by any method well known in the art of pharmacy. The amount of active ingredient that can be combined with carrier materials to produce a single dosage form can vary depending upon the host treated and the particular mode of administration. The amount of active ingredient which, in combination with a carrier material, can produce a single dosage form generally refers to that amount of compound which produces a therapeutic effect.

Dosage forms for topical or transdermal administration of the compounds of this invention may include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and it can be mixed with any preservatives, buffers or propellants that may be required.

When the compounds of the present invention are administered in pharmaceutical form to humans and animals, the compounds may be provided alone or in a pharmaceutical composition containing in combination with a pharmaceutically acceptable carrier active ingredient, for example, 0.1% to 99.5% (more preferably, 0.5% to 90%) of the active ingredient.

Examples of pharmaceutically acceptable carriers include, but are not limited to: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and derivatives thereof such as carboxylate (4) powdered gum tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and Suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol , mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) seaweed (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; (21) cyclodextrin, e.g. linked Targeting ligands in nanoparticles, such as Accurins™; and (22) other non-toxic compatible substances in pharmaceutical formulations, such as polymer-based compositions.

Examples of pharmaceutically acceptable antioxidants include, but are not limited to: (1) water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; ( 2) Oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like. Solid dosage forms (eg, capsules, dragees, dragees, powders, granules, and the like) may include one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or the following Any one of: (1) fillers or bulking agents, such as starch, lactose, sucrose, glucose, mannitol and/or silicic acid; (2) binders, such as carboxymethyl cellulose, alginate, Gelatin, polyvinylpyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (5) dissolution retarders, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) humectants, such as cetyl alcohol and glycerol monostearate; (8) absorption agents such as kaolin and bentonite; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof; and (10) colorants. Liquid dosage forms can include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents; solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzene Methanol, benzyl benzoate, propylene glycol, 1,3-butanediol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerin, tetrahydrofuran methanol, polyethylene Diols and fatty acid esters of sorbitan, and mixtures thereof.

Suspensions, in addition to the active compounds, may also contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum hydroxide oxide, bentonite, agar-agar and tragacanth and mixtures thereof.

Ointments, pastes, creams and gels can contain, in addition to the active compound, excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, poly Ethylene glycol, polysiloxane, bentonite, silicic acid, talc and zinc oxide or mixtures thereof.

Powders and sprays can contain, in addition to the active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. The sprays can contain other customary propellants, such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons, such as butane and propane.

Detailed description of the invention

Unless stated to the contrary, some terms used in the specification and claims of the present invention are defined as follows:

The "bond" means that the indicated substituent does not exist, and both end portions of the substituent are directly connected to form a bond.

"Alkyl" when taken as a group or part of a group is meant to include _C1 - _C20 straight or branched chain aliphatic hydrocarbon groups. Preferably it is a C ₁ -C ₁₀ alkyl group, more preferably a C ₁ -C ₆ alkyl group. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-di Methylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1 -Ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethyl Butyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl Wait. Alkyl groups can be substituted or unsubstituted.

"Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, representative examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. Alkenyl groups can be optionally substituted or unsubstituted.

"Alkynyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon triple bond, which may be straight or branched. Preferred are C2 _{- C10} alkynyl groups, more preferably C2 _{- C6} alkynyl groups, and most preferably C2 _{- C4} alkynyl groups. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, and the like. Alkynyl groups can be substituted or unsubstituted.

"Cycloalkyl" refers to saturated or partially saturated monocyclic, fused, bridged and spirocyclic carbocyclic rings. Preferably it is C ₃ -C ₁₂ cycloalkyl, more preferably C ₃ -C ₈ cycloalkyl, most preferably C ₃ -C ₆ cycloalkyl. Examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptyl Alkenyl, cyclooctyl, etc., preferably cyclopropyl and cyclohexenyl. Cycloalkyl groups can be optionally substituted or unsubstituted.

"Spirocycloalkyl" refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and the single rings share one carbon atom (called spiro atom) with each other, and the ring contains one or more aromatic systems with double bonds but none of the rings have fully conjugated pi electrons. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of spiro atoms shared between the rings, spirocycloalkyl groups are divided into mono-spiro, double-spiro or poly-spirocycloalkyl groups, preferably mono-spiro and double-spirocycloalkyl groups, preferably 4-membered/5-membered, 4-membered Yuan/6 Yuan, 5 Yuan/5 Yuan or 5 Yuan/6 Yuan. Non-limiting examples of "spirocycloalkyl" include, but are not limited to, spiro[4.5]decyl, spiro[4.4]nonyl, spiro[3.5]nonyl, spiro[2.4]heptyl.

"Fused cycloalkyl" refers to a 5- to 18-membered all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms with each other, one or more rings may contain one or more double bonds, But none of the rings have an aromatic system with fully conjugated pi electrons, preferably 6 to 12 membered, more preferably 7 to 10 membered. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicycloalkyl. Non-limiting examples of "fused cycloalkyl" include, but are not limited to: bicyclo[3.1.0]hexyl, bicyclo[3.2.0]hept-1-enyl, bicyclo[3.2.0]heptyl, Decalinyl or tetrahydrophenanthryl.

"Bridged cycloalkyl" refers to an all-carbon polycyclic group of 5 to 18 members, containing two or more cyclic structures, sharing two carbon atoms that are not directly connected to each other, and one or more rings may contain one or more Aromatic systems in which multiple double bonds, but none of the rings have fully conjugated pi electrons, are preferably 6 to 12 membered, more preferably 7 to 10 membered. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of formed rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to: (1s,4s)-bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, (1s,5s)-dicyclo[3.2.1]octyl Cyclo[3.3.1]nonyl, bicyclo[2.2.2]octyl, (1r,5r)-bicyclo[3.3.2]decyl.

"Heterocyclyl," "heterocycle," or "heterocyclic" are used interchangeably herein to refer to a non-aromatic heterocyclyl in which one or more of the ring-forming atoms is a heteroatom, such as oxygen, Nitrogen, sulfur atoms, etc., including monocyclic, fused, bridged and spiro rings. It preferably has a 5- to 7-membered monocyclic ring or a 7- to 10-membered bi- or tricyclic ring, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulfur. Examples of "heterocyclyl" include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxothiomorpholinyl, piperidinyl , 2-oxopiperidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and piperazinyl . Heterocyclyl groups can be substituted or unsubstituted.

"Spiroheterocyclyl" refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and single rings share one atom with each other, and the ring contains one or more double bonds, but no An aromatic system with fully conjugated pi electrons in one ring, wherein one or more ring atoms are selected from nitrogen, oxygen, or a heteroatom of S(O) _r (wherein r is selected from 0, 1, or 2), and the remaining ring atoms are carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan. Spirocycloalkyl groups are classified into mono-spiroheterocyclyl, bis-spiroheterocyclyl or poly-spiroheterocyclyl according to the number of spiro atoms shared between rings, preferably mono-spiroheterocyclyl and bis-spiroheterocyclyl. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered monospiroheterocyclyl group. Non-limiting examples of "spiroheterocyclyl" include, but are not limited to: 1,7-dioxaspiro[4.5]decyl, 2-oxa-7-azaspiro[4.4]nonyl, 7-oxaspiro[4.4]nonyl Heterospiro[3.5]nonyl and 5-oxaspiro[2.4]heptyl.

"Fused heterocyclic group" refers to an all-carbon polycyclic group containing two or more ring structures sharing a pair of atoms with each other, one or more rings may contain one or more double bonds, but no ring has complete Conjugated pi-electron aromatic systems wherein one or more ring atoms are selected from nitrogen, oxygen or heteroatoms of S(O) _r (wherein r is selected from 0, 1 or 2) and the remaining ring atoms are carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic groups. Non-limiting examples of "fused heterocyclyl" include, but are not limited to: octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1H-isoindolyl, 3-azabicyclo[3.1. 0] Hexyl, octahydrobenzo[b][1,4]dioxine or

"Bridged heterocyclyl" refers to a 5- to 14-membered, 5- to 18-membered polycyclic group containing two or more cyclic structures that share two atoms that are not directly connected to each other, and one or more rings may be Aromatic systems containing one or more double bonds but none of the rings have fully conjugated pi electrons, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) _r (wherein r is selected from 0, 1 or 2), the remaining ring atoms are carbon. Preferably it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged heterocyclyl" include, but are not limited to: 2-azabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.2]octyl, and 2-azabicyclo Cyclo[3.3.2]decyl.

"Aryl" refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be joined together in a fused fashion. The term "aryl" includes monocyclic or bicyclic aryl groups such as phenyl, naphthyl, tetrahydronaphthyl aromatic groups. Preferred aryl groups are _C6 - _C10 aryl groups, more preferred aryl groups are phenyl and naphthyl, and most preferred are naphthyl. Aryl groups can be substituted or unsubstituted.

"Heteroaryl" refers to an aromatic 5 to 6 membered monocyclic or 8 to 10 membered bicyclic ring, which may contain 1 to 4 atoms selected from nitrogen, oxygen and/or sulfur. Preferably bicyclic heteroaryl, examples of "heteroaryl" include but are not limited to furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiazolyl oxadiazolyl, benzodioxolyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quinolinyl , Indazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl.

Heteroaryl groups can be substituted or unsubstituted.

"Fused ring" refers to a polycyclic group in which two or more ring structures share a pair of atoms with each other, one or more rings may contain one or more double bonds, but at least one ring is not completely conjugated A pi-electron aromatic system, wherein the ring atoms are selected from 0, one or more heteroatoms selected from nitrogen, oxygen or S(O) _r (wherein r is selected from 0, 1 or 2), and the remaining ring atoms are carbon . The condensed ring preferably includes a bicyclic or tricyclic condensed ring, wherein the bicyclic condensed ring is preferably a condensed ring of an aryl group or a heteroaryl group and a monocyclic heterocyclic group or a monocyclic cycloalkyl group. Preferably it is 7 to 14 yuan, more preferably 8 to 10 yuan. Examples of "fused rings" include, but are not limited to:

"Alkoxy" refers to a group (alkyl-O-). Wherein, alkyl is as defined herein. Ci _{- C6} alkoxy groups are preferred. Examples include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, and the like.

"Haloalkyl" means a group in which an alkyl group is optionally further substituted with one or more halogens, wherein alkyl is as defined herein.

"Hydroxyalkyl" refers to a group in which an alkyl group is optionally further substituted with one or more hydroxy groups, wherein alkyl is as defined herein.

"Methylol" refers to a group in which the methyl group is optionally further substituted with one or more hydroxy groups.

"Haloalkoxy" refers to a group in which the alkyl group of (alkyl-O-) is optionally further substituted with one or more halogens, wherein alkoxy is as defined herein.

"Hydroxy" refers to the -OH group.

"Halogen" refers to fluorine, chlorine, bromine and iodine.

"Amino" refers to _-NH2 .

"Cyano" refers to -CN.

"Nitro" refers to _-NO2 .

"Benzyl" refers to _-CH2 -phenyl.

"Carboxyl" refers to -C(O)OH.

"Carboxylate" means -C(O)O-alkyl or -C(O)O-cycloalkyl, wherein alkyl and cycloalkyl are as defined above.

"DMSO" refers to dimethyl sulfoxide.

"BOC" refers to t-butoxycarbonyl.

"Ts" refers to p-toluenesulfonyl.

"T3P" refers to propylphosphoric anhydride.

"DPPA" refers to diphenylphosphoryl azide.

"DEA" refers to diethylamine.

"X-PHOS Pd G2" refers to chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino- 1,1'-biphenyl)]palladium(II).

"RuPhos Pd G3" methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl) -2-yl)palladium(II).

"cataCXium A Pd-G3" [n-butylbis(1-adamantyl)phosphine](2-amino-1,1'-biphenyl-2-yl)palladium methanesulfonate.

"Pd(dppf)Cl2" refers to [1,1' _- bis(diphenylphosphino)ferrocene]palladium dichloride.

"Substituted" means that one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently of one another, are substituted by the corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the person skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort. For example, amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.

"Substituted" or "substituted" mentioned in this specification, unless otherwise specified, means that the group may be substituted by one or more groups selected from the following groups: alkyl, alkenyl, alkynyl, alkoxy , alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkane Thio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, =O, -C(O)R ⁵ , -C(O)OR ⁵ , -NHC(O)R ⁵ , -NHC(O)OR ⁵ , -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -CH ₂ NHC(O)OR ⁵ , -CH ₂ NR ⁶ R ⁷ or -S(O) _r Replaced by the substituent of R ⁵ ;

R ⁵ is selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclyl group, aryl group or heteroaryl group is optionally further One or more selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, -C (O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , -SO ₂ NR ⁹ R ¹⁰ or -NR ⁹ C (O) Substituents of R ¹⁰ are substituted;

R ⁶ and R ⁷ are each independently selected from a hydrogen atom, a hydroxyl group, a halogen, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, alkoxy group, A cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally further selected from one or more groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl radical, heteroaryl, =O, -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , - SO ₂ NR ⁹ R ¹⁰ or the substituent of -NR ⁹ C(O)R ¹⁰ ;

Alternatively, R ⁶ and R ⁷ together with the atoms to which they are attached form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) _r , and the The 4-8 membered heterocyclic group is optionally further selected from one or more groups selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl , =O, -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , -SO ₂ NR ⁹ R ¹⁰ or -NR ⁹ C(O)R ¹⁰ is substituted by the substituent;

R ⁸ , R ⁹ and R ¹⁰ are each independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclic group , aryl or heteroaryl are optionally further selected from one or more groups selected from hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl , substituted by a substituent of a carboxyl group or a carboxylate group;

r is 0, 1 or 2.

The compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist in different stereoisomeric forms. All stereoisomeric forms of the compounds of the present invention are contemplated, including but not limited to diastereomers, enantiomers, and atropisomers and geometric (conformational) isomers and Their mixtures, such as racemic mixtures, are within the scope of the present invention.

Unless otherwise indicated, the structures depicted herein also include all isomeric (eg, diastereomeric, enantiomeric, and atropisomeric and geometric (conformational) isomeric forms of such structures; for example, , the R and S configuration of each asymmetric center, the (Z) and (E) double bond isomers, and the (Z) and (E) conformational isomers. Thus the individual stereoisomers of the compounds of the present invention as well as Enantiomeric mixtures, diastereomeric mixtures and geometric (conformational) isomer mixtures are all within the scope of the present invention.

"Pharmaceutically acceptable salts" refers to certain salts of the above-mentioned compounds that retain their original biological activity and are suitable for medicinal use. The pharmaceutically acceptable salt of the compound represented by the formula (I) may be a metal salt or an amine salt with a suitable acid.

"Pharmaceutical composition" means a mixture containing one or more of the compounds described herein, or a physiologically pharmaceutically acceptable salt or prodrug thereof, with other chemical components, and other components such as physiologically pharmaceutically acceptable carriers and excipients Form. The purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.

Synthetic method of the compound of the present invention

In order to accomplish the purpose of the present invention, the present invention adopts following technical scheme:

The preparation method of the compound described in the general formula (I) of the present invention or its stereoisomer, tautomer or its pharmaceutically acceptable salt comprises the following steps:

The compound of general formula (IA) and the compound of general formula (IB) are subjected to a Suzuki coupling reaction under the action of a palladium catalyst and a basic reagent to obtain a compound of general formula (IC); the compound of general formula (IC) is further deprotected, and any Select to further remove the protecting group on ring B to obtain the compound of general formula (I);

in:

X is a leaving group, preferably chlorine;

PG is a protecting group, preferably tert-butoxycarbonyl;

M is selected from -B(OH) ₂ , -BF ₃ K or

Ring B, R ¹ to R ⁴ , Q, Y, m and n are as defined in the general formula (I).

Detailed ways

The following examples are used to further describe the present invention, but these examples do not limit the scope of the present invention.

Example

The examples give the preparation and related structural identification data of the representative compounds represented by formula (I). It must be noted that the following examples are used to illustrate the present invention rather than limit it. The ¹ H NMR spectrum was measured with a Bruker instrument (400 MHz), and the chemical shifts were expressed in ppm. A tetramethylsilane internal standard (0.00 ppm) was used. ¹ HNMR representation: s=singlet, d=doublet, t=triplet, m=multiplet, br=broadened, dd=doublet of doublet, dt=doublet of triplet. When coupling constants are provided, they are in Hz.

Mass spectrum is obtained by LC/MS instrument, and the ionization mode can be ESI or APCI.

The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, the size of the silica gel plate used for thin layer chromatography (TLC) is 0.15mm ~ 0.2mm, and the size of the TLC separation and purification products is 0.4mm ~0.5mm.

Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

In the following examples, all temperatures are in degrees Celsius unless otherwise indicated, and various starting materials and reagents were obtained from commercially available or synthesized according to known methods without further purification. For direct use, unless otherwise specified, commercially available manufacturers include but are not limited to Shanghai Haohong Biomedical Technology Co., Ltd., Shanghai Shaoyuan Reagent Co., Ltd., Shanghai Bide Pharmaceutical Technology Co., Ltd., Saen Chemical Technology (Shanghai) Co., Ltd. and Shanghai Lingkai Pharmaceutical Technology Co., Ltd., etc.

_CD3OD : Deuterated methanol.

CDCl ₃ : deuterated chloroform.

DMSO-d ₆ : deuterated dimethyl sulfoxide.

There is no special description in the examples, and the solution in the reaction refers to an aqueous solution.

The compound was purified using column chromatography and thin layer chromatography eluent system, wherein the system was selected from: A: petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: dichloromethane And ethyl acetate system, D: dichloromethane and ethanol system, wherein the volume ratio of the solvent varies according to the polarity of the compound, and a small amount of acidic or basic reagents can also be added for conditions, such as acetic acid or triethylamine.

Room temperature: 20℃～30℃.

Example 1

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin -7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-fluoronaphthalen-2-ol

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetra Hydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-fluoronaphthalen-2-ol

first step

tert-butyl(1R,5S)-8-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

(1R,5S)-8-(2,7-Dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane -3-Carboxylic acid tert-butyl ester

2,4,7-Trichloro-8-fluoropyrido[4,3-d]pyrimidine 1a (1.1 g, 4.36 mmol) was dissolved in dichloromethane (19.96 mL) and N,N-diisopropyl was added Ethylamine (3.94g, 30.50mmol, 5.04mL), cooled to -40°C, added (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1b (924.96 mg, 4.36 mmol) was reacted at room temperature for 1 hour. After the reaction, water (10 mL) was added, extracted with dichloromethane (20 mL), the organic phase was washed with saturated brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and the obtained residue was subjected to silica gel column chromatography method (eluent: A system) to obtain the product (1R,5S)-8-(2,7-dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3 , 8-Diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1c (750 mg, 1.75 mmol), 40.19% yield.

LC/MS: 427.9[M+H] ⁺

second step

tert-butyl(1R,5S)-8-(7-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4 ,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

(1R,5S)-8-(7-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrroazin-7a(5H)-yl)methoxy)pyridine [4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester

(1R,5S)-8-(2,7-Dichloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane tert-Butyl alkane-3-carboxylate 1c (750 mg, 1.75 mmol), ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methanol 1d (362.42 mg, 2.28 mmol) ), 4A type molecular sieve (7.71g, 17.51mmol) and N,N-diisopropylethylamine (678.96mg, 5.25mmol, 868.24μL) were dissolved in 1,4-dioxane (3.28mL), heated The reaction was carried out at 90°C for 3 hours. After the reaction was completed, filtered, the filtrate was washed with saturated brine (100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was separated by silica gel column chromatography (eluent: system B) Purification to give the product (1R,5S)-8-(7-chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methan oxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1e (500 mg, 907.40 μmol), Yield 51.82%.

LC/MS: 552.1[M+H] ⁺

third step

tert-butyl(1R,5S)-8-(8-fluoro-7-(8-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H -pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

(1R,5S)-8-(8-Fluoro-7-(8-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-2-(((2R,7aS)-2-fluoro Tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane -3-Carboxylic acid tert-butyl ester

(1R,5S)-8-(7-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy) Pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1e (200 mg, 362.96 μmol), 2-( 8-Fluoro-3-(methoxymethoxy)naphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane 1f (168.79mg, 508.14 μmol), potassium phosphate (231.14 mg, 1.09 mmol) and cataCXium A Pd-G3 (264.70 mg, 362.96 μmol) were dissolved in tetrahydrofuran (5 mL), and heated to 60° C. for 2 hours under argon protection. After the reaction, water (10 mL) was added, extracted with ethyl acetate (10 mL), the organic phase was washed with saturated brine (100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was used Silica gel column chromatography (eluent: A system) was isolated and purified to obtain the product (1R,5S)-8-(8-fluoro-7-(8-fluoro-3-(methoxymethoxy)naphthalene-) 1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidine-4- yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1 g (180 mg, 249.73 μmol), yield 68.80%.

LC/MS: 721.1[M+H] ⁺

the fourth step

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin -7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-fluoronaphthalen-2-ol

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetra Hydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-fluoronaphthalen-2-ol

(1R,5S)-8-(8-Fluoro-7-(8-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-2-(((2R,7aS)-2- Fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane 1 g (180.00 mg, 249.73 μmol) of tert-butyl alkane-3-carboxylate was dissolved in acetonitrile (5 mL), 4M HCl in 1,4-dioxane solution (5 mL) was added at 0°C, and the reaction was carried out at room temperature for 0.5 Hour. After the reaction, water (10 mL) was added, extracted with dichloromethane (20 mL×2), the organic phases were combined, washed with saturated brine (100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure , the obtained residue was purified by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm I.D.; 5 μm, 20 mL/min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to obtain product 4 -(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro -1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-fluoronaphthalen-2-ol 1 (30 mg, 52.03 μmol), yielded rate 20.83%.

LC/MS: 577.1[M+H] ⁺

¹ H NMR(500MHz, DMSO-d)δ9.45(s,1H),8.51(m,J=2.4Hz,1H),8.32(d,J=2.2Hz,1H),7.40(t,J=7.8 Hz, 1H), 7.16(t, J=2.2Hz, 1H), 7.11(t, J=7.9Hz, 1H), 7.04(s, 1H), 5.43-5.37(m, 1H), 4.40(d, J ＝10.8Hz,1H),4.23(d,J＝10.8Hz,1H),3.83(m,J＝4.3Hz,2H),3.22(m,J＝2.6Hz,1H),3.17-3.03(m,4H) ), 2.79(t, J=12.1Hz, 2H), 2.69-2.61(m, 1H), 2.06(m, J=3.1Hz, 1H), 2.01-1.94(m, 2H), 1.94-1.88(m, 2H),1.88-1.65(m,6H).

Example 2

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin -7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetra Hydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

first step

tert-butyl(1R,5S)-8-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(((2R ,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)- yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3- carboxylate

(1R,5S)-8-(8-Fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalene-1- yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrozin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl) -3,8-Diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester

(1R,5S)-8-(7-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy) Pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1e (279.04 mg, 544.44 μmol), (( 2-Fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaboroboran-2-yl)naphthalene-1 -yl)ethynyl)triisopropylsilane 2a (279.04 mg, 544.44 μmol), cesium carbonate (236.52 mg, 725.92 μmol) and Pd(dppf)Cl ₂ (29.64 mg, 36.30 μmol) dissolved in 1,4-di In a mixed solvent of oxane (6 mL) and water (2 mL), under argon protection, heated to 110° C. to react for 2 hours. After the reaction, water (10 mL) was added, extracted with ethyl acetate (20 mL), the organic phase was washed with saturated brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was used Separation and purification by silica gel column chromatography (eluent: A system) to obtain the product (1R,5S)-8-(8-fluoro-7-(7-fluoro-3-(methoxymethoxy)-8) -((triisopropylsilyl)ethynyl)naphthalen-1-yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrroazin-7a(5H)-yl)methyl oxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 2b (100 mg, 110.97 μmol), Yield 30.57%.

LC/MS: 902.1[M+H] ⁺

second step

tert-butyl(1R,5S)-8-(7-(8-ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)-2 -fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

(1R,5S)-8-(7-(8-Ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((((2R,7aS )-2-fluorotetrahydro-1H-pyrroazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2 .1] Octane-3-carboxylate tert-butyl ester

(1R,5S)-8-(8-Fluoro-7-(7-fluoro-3-(methoxymethoxy)-8-((triisopropylsilyl)ethynyl)naphthalene-1 -yl)-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrozin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl )-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 2b (100 mg, 110.97 μmol) was dissolved in N,N-dimethylformamide (2 mL) and added with fluorine Cesium (84.28 mg, 554.85 μmol) was reacted at room temperature for 0.5 hours. After the reaction, water (10 mL) was added, extracted with ethyl acetate (10 mL), the organic phase was washed with saturated brine (10 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product (1R ,5S)-8-(7-(8-Ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-(((2R,7aS)- 2-Fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1 ] Octane-3-carboxylate tert-butyl ester 2c (80 mg, 107.41 μmol), 96.79% yield.

LC/MS: 745.1[M+H] ⁺

third step

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin -7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetra Hydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol

(1R,5S)-8-(7-(8-Ethynyl-7-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-8-fluoro-2-((((2R, 7aS)-2-Fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[ 3.2.1] Octane-3-carboxylate tert-butyl ester 2c (80.00 mg, 107.41 μmol) was dissolved in acetonitrile (2 mL), 4M HCl in 1,4-dioxane solution (1 mL) was added, and the room temperature React for 1 hour. Concentrated under reduced pressure, the obtained residue was purified by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm I.D.; 5 μm, 20 mL/min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to obtain Product 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-((((2R,7aS)-2-fluoro Tetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol 2( 10 mg, 16.65 μmol), 15.50% yield.

LC/MS: 601.1[M+H] ⁺

¹ H NMR(500MHz, DMSO-d)δ9.01(s,1H),8.27(m,J=3.6Hz,1H),7.64(d,J=2.2Hz,1H),7.28(t,J=8.3 Hz, 1H), 7.20(t, J=2.0Hz, 1H), 7.16(s, 1H), 5.52-5.38(m, 1H), 4.43-4.25(m, 2H), 4.21(m, J=7.9Hz) ,2H),3.44(s,1H),3.23(t,J=8.4Hz,2H),3.02(t,J=12.1Hz,2H),2.97-2.87(m,2H),2.62-2.55(m, 1H), 2.10-1.97(m, 2H), 1.95-1.70(m, 10H).

Example 3

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin -7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5,7-difluorobenzo[d]thiazol-2-amine

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetra Hydro-1H-pyrroazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5,7-difluorobenzo[d]thiazol-2-amine

first step

tert-butyl(1R,5S)-8-(7-(2-((tert-butoxycarbonyl)amino)-5,7-difluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(((( 2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3 -carboxylate

(1R,5S)-8-(7-(2-((tert-butoxycarbonyl)amino)-5,7-difluorobenzo[d]thiazol-4-yl)-8-fluoro-2-(( (2R,7aS)-2-Fluorotetrahydro-1H-pyrrozin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diaza Heterobicyclo[3.2.1]octane-3-carboxylate tert-butyl ester

(1R,5S)-8-(7-Chloro-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy) Pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 1e (100 mg, 181.48 μmol), (2- ((tert-Butoxycarbonyl)amino)-5,7-difluorobenzo[d]thiazol-4-yl)boronic acid 3a (89.86 mg, 272.22 μmol, prepared according to published patent US20200115375A1), sodium carbonate (57.71 mg, 544.44 μmol) and tetrakistriphenylphosphine palladium (20.97 mg, 18.15 μmol) were dissolved in 1,4-dioxane (5 mL), under argon protection, heated to 110° C. to react for 5 hours. After the reaction, the reaction solution was filtered, and the obtained residue was separated and purified by preparative liquid phase (separation column AKZONOBEL Kromasil; 250×21.2 mm I.D.; 5 μm, 20 mL/min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) to give the product (1R,5S)-8-(7-(2-((tert-butoxycarbonyl)amino)-5,7-difluorobenzo[d]thiazol-4-yl)-8-fluoro -2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrroazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3 ,8-Diazabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 3b (45 mg, 56.19 μmol), 30.96% yield.

LC/MS: 800.9[M+H] ⁺

second step

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin -7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5,7-difluorobenzo[d]thiazol-2-amine

4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetra Hydro-1H-pyrroazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5,7-difluorobenzo[d]thiazol-2-amine

(1R,5S)-8-(7-(2-((tert-butoxycarbonyl)amino)-5,7-difluorobenzo[d]thiazol-4-yl)-8-fluoro-2-( ((2R,7aS)-2-Fluorotetrahydro-1H-pyrrolazin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-4-yl)-3,8-di Azabicyclo[3.2.1]octane-3-carboxylate tert-butyl ester 3b (30 mg, 37.46 μmol) was dissolved in dichloromethane (5 mL) and 4M HCl in 1,4-dioxane was added ( 5 mL) and reacted overnight at room temperature. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by preparative liquid phase separation (separation column AKZONOBEL Kromasil; 250×21.2 mm I.D.; 5 μm, 20 mL/min; mobile phase A: 0.05% TFA+H2O, mobile phase B: CH3CN) , the product 4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]oct-8-yl)-8-fluoro-2-((((2R,7aS)-2 -Fluorotetrahydro-1H-pyrrozin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5,7-difluorobenzo[d]thiazole- 2-amine 3 (3 mg, 4.79 μmol), 12.80% yield.

LC/MS: 600.9[M+H] ⁺

Biological evaluation

Test Example 1. Determination of the Inhibitory Activity of the Compounds of the Invention on p-ERK1/2 in AGS Cells

The following method was used to determine the inhibitory activity of the compounds of the present invention on p-ERK1/2 in AGS cells. This method uses the Advanced phospho-ERK1/2 (Thr202/tyr204) kit (Cat. No. 64AERPEH) from Cisbio Company. For detailed experimental operation, please refer to the kit instructions. AGS cells (containing KRAS G12D mutation) were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

The experimental procedure is briefly described as follows: AGS cells were cultured in F12K complete medium containing 10% fetal bovine serum, 100 U penicillin and 100 μg/mL streptomycin. AGS cells were plated in 96-well plates at 40,000 cells per well, and the medium was complete medium, and cultured overnight in a 37° C., 5% CO2 incubator. The test compound was dissolved in DMSO to prepare a 10mM stock solution, then diluted with F12K complete medium, and 100uL of F12K complete medium containing the corresponding concentration of the test compound was added to each well. The final concentration range of the test compound in the reaction system After culturing in a cell incubator for 3 hours, discard the cell supernatant, wash the cells with ice-bathed PBS, and then add 50 μl of 1×cell phospho/total protein lysis buffer (Advanced phospho-ERK1 /2 kit components) for lysis, the 96-well plate was placed on ice for half an hour, and then the lysate was detected according to the instructions of the Advanced phospho-ERK1/2 (Thr202/tyr204) kit. Finally, under the excitation wavelength of 304nM, the fluorescence intensity of each well at 620nM and 665nM was measured on a microplate reader in TF-FRET mode, and the fluorescence intensity ratio of 665/620 in each well was calculated. By comparing with the control group (0.1%

The ratio of fluorescence intensity of DMSO) was compared, the percentage inhibition rate of the test compound at each concentration was calculated, and a nonlinear regression analysis was performed on the value-inhibition rate of the test compound concentration by GraphPad Prism 5 software to obtain the IC ₅₀ value of the compound. .

The preferred compound of the present invention has obvious inhibitory effect on the activity of p-ERK1/2 in AGS cells, the preferred compound has an IC ₅₀ <500nM, and the more preferred compound has an IC ₅₀ <200nM.

Test Example 2. The compound of the present invention inhibits the proliferation of AsPC-1 cells

The following method was used to determine the effect of the compounds of the present invention on the proliferation of AsPC-1 (metastatic pancreatic adenocarcinoma) cells. AsPC-1 cells (containing KRAS G12D mutation) were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in RPMI 1640 medium containing 10% fetal bovine serum, 100 U penicillin, 100 μg/mL streptomycin and 1 mM Sodium Pyruvate middle. cell viability through

Assays were performed with the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).

The experimental method was operated according to the steps in the kit instructions, which are briefly described as follows: the test compound was first dissolved in DMSO to prepare a 10 mM stock solution, and then diluted with culture medium to prepare a test sample. The final concentration of the compound was in the range of 1000nM-0.015nM . Cells in logarithmic growth phase were seeded into 96-well cell culture plates at a density of 800 cells per well, cultured overnight at 37°C in a 5% CO2 incubator, followed by the addition of test compounds for 120 hours. After the incubation, 50uL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and then allowed to stand for 10 minutes. Then, the luminescence value of each well of the sample was read on a microplate reader using Luminescence mode. The percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO), and then a nonlinear regression analysis was performed in the GraphPad Prism 5 software with the compound concentration logarithm-inhibition rate to obtain the compound inhibiting cell proliferation. the _IC50 value.

The preferred compound of the present invention has obvious inhibitory effect on the proliferation of AsPC-1 cells, the preferred compound has an IC ₅₀ <500nM, and the more preferred compound has an IC ₅₀ <200nM.

Test Example 3. Determination of the inhibitory ability of the compounds of the present invention on the interaction between KRAS G12D and RAF1 protein

The following method was used to determine the ability of the compounds of the invention to block the KRAS G12D:RAF1 protein interaction under in vitro conditions. This method uses the KRAS-G12C/SOS1 BINDING ASSAY KITS kit (63ADK000CB21PEG) from Cisbio Company, and the detailed experimental operation can be referred to the kit instructions.

The experimental process is briefly described as follows: Use diluent buffer (Cat. No. 62DLBDDF) to configure the working solution concentration of Tag1-RAF1 and Tag2-KRAS-G12D proteins to 5X for use. Test compounds were dissolved in DMSO to prepare 10 mM stock solutions, which were then diluted with diluent buffer for use. First add 2uL of the test compound to the well (the final concentration of the reaction system is 10000nM-0.1nM), then add 4uL of Tag1-RAF1 5X working solution and 4uL of Tag2-KRAS-G12D 5X working solution, centrifuge and mix well, let stand 15 minutes; then add 10uL of pre-mixed anti-Tag1-Eu ³⁺ and anti-Tag2-XL665, and incubate for 4 hours at room temperature; finally, use a microplate reader to measure in TF-FRET mode at an excitation wavelength of 304 nm. The wells emit fluorescence intensities at wavelengths of 620 nm and 665 nm, and the 665/620 fluorescence intensity ratio of each well is calculated. By comparing the fluorescence intensity ratio with the control group (0.1% DMSO), the percentage inhibition rate of the test compound at each concentration was calculated, and the numerical-inhibition rate was subjected to nonlinear regression analysis with the test compound concentration by GraphPad Prism 5 software. , the _IC50 values of the compounds were obtained, see Table 1 below.

Table 1 Data on the inhibitory ability of the compounds of the present invention on the interaction between KRAS G12D and RAF1 protein

Example number	IC50 (nM)
1	141
2	317
3	331

Conclusion: The compound of the present invention has a good inhibitory ability on the interaction between KRAS G12D and RAF1 protein.

Test Example 4. Inhibitory assay of the compounds of the present invention on AGS cell proliferation

The following method was used to determine the effect of the compounds of the present invention on the proliferation of AGS (human gastric adenocarcinoma) cells. AGS cells (containing KRAS G12D mutation) were purchased from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and cultured in F-12K medium containing 10% fetal bovine serum, 100 U penicillin and 100 μg/mL streptomycin. cell viability through

Assays were performed with the Luminescent Cell Viability Assay Kit (Promega, Cat. No. G7573).

The experimental method was operated according to the steps in the kit instructions, which are briefly described as follows: the test compound was first dissolved in DMSO to prepare a 10 mM stock solution, and then diluted with culture medium to prepare a test sample. The final concentration of the compound was in the range of 1000nM-0.015nM . Cells in logarithmic growth phase were seeded into 96-well cell culture plates at a density of 500 cells per well, cultured overnight at 37°C in a 5% _CO2 incubator, followed by the addition of test compounds for 72 hours. After the incubation, 50uL of CellTiter-Glo detection solution was added to each well, shaken for 5 minutes, and then allowed to stand for 10 minutes. Then, the luminescence value of each well of the sample was read on a microplate reader using Luminescence mode. The percentage inhibition rate of the compound at each concentration point was calculated by comparing it with the value of the control group (0.3% DMSO), and then a nonlinear regression analysis was performed in the GraphPad Prism 5 software with the compound concentration logarithm-inhibition rate to obtain the compound inhibiting cell proliferation. The _IC50 values are shown in Table 2.

Table 2 IC ₅₀ data of the compounds of the present invention for inhibiting the proliferation of AGS cells

Example number	IC50 (nM)
1	68
2	93

Conclusion: The compound of the present invention has a good inhibitory effect on the proliferation of AGS cells.

Claims (17)

1. A compound represented by the general formula (I) or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof:

   

   in:

   Ring B is selected from aryl, heteroaryl or fused rings;

   Q is selected from N or CR ^a ;

   Y is selected from a bond, -O- or ^-NRb ;

   R ^a is selected from hydrogen atom, halogen, alkyl, alkoxy or cyano; wherein said alkyl or alkoxy is optionally further selected from one or more halogens, hydroxy, cyano, alkyl or alkane substituted by an oxy substituent;

   R ^b is selected from a hydrogen atom or an alkyl group;

   R ^c is selected from hydrogen atom, halogen, cyano, alkyl or alkoxy; wherein said alkyl or alkoxy is optionally further selected by one or more of halogen, hydroxy, cyano, alkyl or alkoxy substituted by the substituent of oxy; R ^c is preferably halogen, more preferably fluorine or chlorine;

   R ¹ is selected from -L-cycloalkyl, -L-(6-membered to 9-membered) monocyclic heterocyclic group, -L-bicyclic heterocyclic group, -L-tricyclic heterocyclic group, -L-aryl, -L-heteroaryl or -L- fused ring; wherein said cycloalkyl, (6-9 membered) monocyclic heterocyclic group, bicyclic heterocyclic group, -tricyclic heterocyclic group, aryl, The heteroaryl or fused ring is optionally further selected from one or more groups selected from the group consisting of alkyl, halogen, haloalkyl, hydroxyalkyl, benzyl, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl base, =O, -OR ⁵ , -C(O)R ⁵ , -C(O)OR ⁵ , -NHC(O)R ⁵ , -NHC(O)OR ⁵ , -NR ⁶ R ⁷ , -C( O) NR ⁶ R ⁷ , -CH ₂ NHC(O)OR ⁵ , -CH ₂ NR ⁶ R ⁷ or -S(O) _r R ⁵ substituent;

   L is each independently selected from a bond or a -C ₁ -C ₆ alkylene group, wherein said alkylene group is optionally further substituted with one or more R ^D ;

   R ^D is each independently selected from a hydrogen atom, halogen, hydroxy or hydroxymethyl;

   Alternatively, two R ^D attached to the same carbon atom, together with the attached carbon atom, form a cycloalkyl; preferably cyclopropyl;

   R ² are the same or different, each independently selected from hydrogen atom, halogen, hydroxyl, alkyl or alkoxy, preferably hydrogen atom or alkyl;

   The two ^R3 together with the atoms to which they are attached form a cycloalkyl or heterocyclyl;

   The condition is that when Q is chosen from N,

   

   not selected

   

   R ⁴ are the same or different, each independently selected from a hydrogen atom, an alkyl group, a halogen, a nitro group, a cyano group, an alkenyl group, an alkynyl group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, =O, - OR ⁵ , -C(O)R ⁵ , -C(O)OR ⁵ , -NHC(O)R ⁵ , -NHC(O)OR ⁵ , -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -CH ₂ NHC(O)OR ⁵ , -CH ₂ NR ⁶ R ⁷ or -S(O) _r R ⁵ ; wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl The radical or heteroaryl is optionally further selected from one or more of alkyl, halogen, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O, ^-OR5 , -C (O)R ⁵ , -C(O)OR ⁵ , -NHC(O)R ⁵ , -NHC(O)OR ⁵ , -NR ⁶ R ⁷ , -C(O)NR ⁶ R ⁷ , -CH ₂ NHC (O) OR ⁵ , -CH ₂ NR ⁶ R ⁷ or -S(O) _r R ⁵ substituent;

   R ⁵ is each independently selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclyl group, aryl group or heteroaryl group is any selected further by one or more selected from the group consisting of hydroxy, halogen, nitro, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =O , -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , -SO ₂ NR ⁹ R ¹⁰ or - Substituted by the substituent of NR ⁹ C(O)R ¹⁰ ;

   R ⁶ and R ⁷ are each independently selected from a hydrogen atom, a hydroxyl group, a halogen, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, alkoxy group, A cycloalkyl, heterocyclyl, aryl or heteroaryl group is optionally further selected from one or more groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl radical, heteroaryl, =O, -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , - SO ₂ NR ⁹ R ¹⁰ or the substituent of -NR ⁹ C(O)R ¹⁰ ;

   Alternatively, R ⁶ and R ⁷ together with the atoms to which they are attached form a 4- to 8-membered heterocyclic group, wherein the 4- to 8-membered heterocyclic group contains one or more N, O or S(O) _r , and the The 4-8 membered heterocyclic group is optionally further selected from one or more groups selected from hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl , =O, -C(O)R ⁸ , -C(O)OR ⁸ , -OC(O)R ⁸ , -NR ⁹ R ¹⁰ , -C(O)NR ⁹ R ¹⁰ , -SO ₂ NR ⁹ R ¹⁰ or -NR ⁹ C(O)R ¹⁰ is substituted by the substituent;

   R ⁸ , R ⁹ and R ¹⁰ are each independently selected from a hydrogen atom, an alkyl group, an amino group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocyclic group , aryl or heteroaryl are optionally further selected from one or more groups selected from hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl , substituted by a substituent of a carboxyl group or a carboxylate group;

   m is selected from 0, 1, 2, 3 or 4;

   n is selected from 0, 1, 2 or 3;

   r is 0, 1 or 2.
2. The compound represented by the general formula (I) according to claim 1 or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, which is a compound represented by the general formula (II) or a stereoisomer thereof Isomers, tautomers or pharmaceutically acceptable salts thereof:

   

   wherein: Ring B, R ¹ , R ² , R ⁴ , R ^c , Y, m and n are as defined in claim 1 .
3. The compound according to claim 1 or 2 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein:

   R ¹ is -L-bicyclic heterocyclic group; wherein said bicyclic heterocyclic group is optionally further substituted by one or more substituents selected from alkyl, halogen, alkoxy or =O; wherein said Halogen is preferably fluorine;

   L is selected from a bond or a -C ₁ -C ₃ alkylene group, wherein said alkylene group is optionally further substituted by one or more R ^D ;

   R ^D is each independently selected from a hydrogen atom, halogen, hydroxy or hydroxymethyl;

   Alternatively, two R ^D , attached to the same carbon atom, together with the attached carbon atom form a cycloalkyl; preferably cyclopropyl.
4. The compound of claim 3 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein:

   L is selected from bond, -CH ₂ -, -CH ₂ CH ₂ - or

   
5. The compound according to claim 3 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ¹ is selected from:

   
6. The compound according to any one of claims 1 to 5, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein two R ³ together with the atoms to which they are attached form a 4-8 membered Cycloalkyl or 4-8 membered heterocyclic group.
7. The compound according to any one of claims 1 to 6 or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:

   R ⁴ are the same or different, each independently selected from a hydrogen atom, an alkyl group, a halogen, an alkoxy group, an alkynyl group, a hydroxyl group, an amino group, a hydroxyalkyl group, a haloalkyl group or a haloalkoxy group; preferably a hydrogen atom, a methyl group, a fluoro group , chlorine, hydroxyl, amino, methylol or ethynyl.
8. The compound according to any one of claims 1 to 7 or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein:

   Ring B is selected from phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, indolyl, indazolyl, benzothiazolyl, tetralinyl,

   

   Preferred are naphthyl and benzothiazolyl.
9. The compound according to any one of claims 1 to 8 or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, wherein

   

   selected from the following groups:

   
10. The compound of claim 1 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein

    

    selected from the following groups:

    
11. The compound according to any one of claims 1 to 10 or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R ^c is selected from halogen, preferably fluorine.
12. The compound according to claim 1 or its stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein said compound is:

    
13. A pharmaceutical composition comprising an effective dose of the compound according to any one of claims 1 to 12 or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carriers, excipients or their combinations.
14. The compound according to any one of claims 1 to 12 or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 13 is used in the preparation of KRas G12D inhibition use in medicaments.
15. The compound according to any one of claims 1 to 12 or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 13 is prepared for treatment by KRas Use in the medicine of the disease mediated by G12D mutation, wherein the disease mediated by KRas G12D mutation is selected from cancer, wherein the cancer is selected from cardiac myxoma, lung cancer, gastric cancer, colorectal cancer, rectal cancer, Pancreatic cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, cholangiocarcinoma, chondrosarcoma, multiple myeloma, uterine cancer, cervical cancer, seminoma, malignant melanoma, skin squamous cell carcinoma, adrenal neuroblastoma , myeloid leukemia, acute lymphoblastic leukemia or glioblastoma, preferably pancreatic cancer, colorectal cancer, rectal cancer and lung cancer.
16. The compound according to any one of claims 1 to 12 or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 13 is used in the preparation of the treatment of cancer. Use in medicine, wherein the cancer is selected from cardiac myxoma, lung cancer, gastric cancer, colorectal cancer, rectal cancer, pancreatic cancer, prostate cancer, bladder cancer, hepatocellular carcinoma, cholangiocarcinoma, chondrosarcoma, multiple myeloma , uterine cancer, cervical cancer, seminoma, malignant melanoma, cutaneous squamous cell carcinoma, adrenal neuroblastoma, myeloid leukemia, acute lymphoblastic leukemia or glioblastoma, preferably pancreatic cancer, colorectal cancer cancer, rectal cancer and lung cancer.
17. The use according to claim 15 or 16, wherein the lung cancer is selected from non-small cell lung cancer or small cell lung cancer.